Aromatase inhibitors in the treatment and prevention of breast cancer

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 881-894

  Goss, P E ^a   Strasser, K ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE; TAMOXIFEN; VOROZOLE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; GASTROINTESTINAL SYMPTOM; HUMAN; PRIORITY JOURNAL; RASH; REVIEW;

EID: 0035253379     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.881     Document Type: Review

References (111)

1. Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer
2. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover
3. Estrogen and risk of breast cancer
4. Role of extraglandular estrogen in human endocrinology
5. Aromatase expression in health and disease
6. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
7. Pharmacology of new aromatase inhibitors
8. Clinical use of aromatase inhibitors in human breast carcinoma
9. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer
10. Aminoglutethimide in the treatment of premenopausal patients with breast cancer
11. Resistance of the ovary to blockade of aromatization with aminoglutethimide
12. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer
13. Naftolin: The potential of aromatase inhibitors in breast cancer prevention
14. Concentration of sex steroids in adipose tissue after menopause
15. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer
16. Oestradiol synthesis from C 19 steroids by human breast cancers
17. A reassessment of the role of breast tumor aromatization
18. Biological significance of aromatase activity in human breast tumors
19. A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription
20. Aberrant expression of aromatase in breast cancer tissues
21. Aromatase activity in normal breast and breast tumor tissues: In vivo and in vitro studies
22. The importance of local synthesis of estrogen within the breast
23. Regulation of aromatase activity within the breast
24. Aromatase inhibitors and their antitumor effects in model systems
25. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities
26. Aromatase overexpression and breast hyperplasia, an in vivo model: Continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands
27. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells
28. Relationship between tumour aromatase activity, tumour characteristics and response to therapy
29. Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging
30. Studies on the mechanism of estrogen biosynthesis in the rat ovary
31. Aromatase inhibitors and their potential clinical significance
32. Current perspectives on aromatase inhibitors in breast cancer
33. Letrozole suppresses plasma estrogen levels in postmenopausal breast cancer patients more completely than anastrozole
34. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors
35. Experimentally induced mammary tumors in rats
36. Animal models of breast cancer: Experimental design and their use in nutrition and psychosocial research
37. Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor
38. Characterization of a silencer element in the human aromatase gene
39. A nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene
40. Aromatase inhibitors: Mechanisms of steroidal inhibitors
41. Aromatase inhibitors: Mechanisms for non-steroidal inhibitors
42. Pharmacology of inhibitors of estrogen biosynthesis
43. Aromatase inhibitors: Rationale for use following anti-oestrogen therapy
44. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
45. Clinical significance of tamoxifen withdrawal response
46. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancer: The Arimidex Study Group
47. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer: The Arimidex Study Group
48. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview and analysis of two phase III clinical trials - The Arimidex Study Group
49. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: The Arimidex Study Group
50. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer - The Letrozole International Trial Group
51. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
52. A phase III trial comparing vorozole (RIVIZOR) versus aminoglutethimide in the treatment of advanced postmenopausal breast cancer: The Vorozole Study Group
53. Vorozole (Rivizor) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen
54. Randomized phase m trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients: The North American Vorozole Study Group
55. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial - The Exemestane Study Group
56. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
57. Fadrozole HCl (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: The Multi-Institutional Trialist Collaborative Study Group
58. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment - The Swiss Group for Clinical Cancer Res
59. Liarozole fumarate (R85246): A novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer
60. Liarozole fumarate (R85246): In the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer
61. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
62. A phase II confirmatory study of antitumor efficacy and safety of exemestane (EXE) as third-line hormonal treatment of postmenopausal patients (pts) with metastatic breast cancer (MBC) refractory to tamoxifen (Tam) and Megace
63. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer
64. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy
65. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer
66. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study - The Exemestane Study Group
67. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial
68. Tamoxifen (TAM) vs aminoglutethimide in breast cancer patients previously treated with adjuvant TAM: Preliminary results of a multicentric comparative study
69. The effects of aromatase inhibitors and antiestrogens in the nude mouse model
70. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal women: Combined analyses from two identically designed multicenter trials
71. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer
72. Tamoxifen versus aminoglutethimide in the treatment of advanced breast carcinoma
73. Hormonal treatment of metastatic breast cancer: An Eastern Cooperative Oncology Group Phase III trial comparing aminoglutethimide to tamoxifen
74. First-line fadrozole HCl (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: The Swiss Group for Clinical Cancer Res (SAKK)
75. Vorozole Study Group: A randomised multicentre study of vorozole compared to tamoxifen as primary therapy in post-menopausal breast cancer
76. Letrozole as primary medical therapy for locally advanced and large operable breast cancer
77. Arimidex as neoadjuvant therapy causes large reductions in tumour volume in postmenopausal women with large operable breast cancers
78. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intratumor estrogen levels
79. The effects of letrozole on in site and in vitro oestrogen synthesis and endogenous oestrogen within the breast
80. Is estradiol a genotoxic mutagenic carcinogen?
81. Overexpression of int-5/aromatase in transgenic male mice leads to gynecomastia and testicular cancer
82. Tamoxifen for early breast cancer: An overview of the randomised trials
83. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1
84. Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: Toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone
85. Antitumoral and endocrine effects of (+)-vorozole in rats beating dimethylbenzanthracene-induced mammary tumors
86. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats
87. CGS 16949A, a new nonsteroidal aromatase inhibitor: Effects on hormone-dependent and -independent tumors in vivo
88. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen dependent rat mammary tumors
89. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor
90. Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study
91. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study
92. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients
93. Aromatase inhibitors in human breast cancer
94. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced post-menopausal breast cancer
95. Tamoxifen and aminoglutethimide in advanced breast cancer
96. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer
97. A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer
98. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially
99. Combined endocrine treatment of postmenopausal patients with advanced breast cancer
100. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
101. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetics interaction in postmenopausal women with metastatic breast cancer
102. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
103. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
104. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer: A Southwest Oncology Group phase III trial
105. Prospective randomized study of aminoglutethimide (AG) versus medroxyprogesterone acetate (MPA) versus AG+MPA in generalized breast cancer
106. Aminoglutethimid plus hochdosiertes Medroxyprogesteronazetat versus Aminoglutethimid plus Kortison in der Therapie des metastasierenden Mammakarzinoms
107. Qualitative effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast
108. Aromatization of androgens is important for skeletal maintenance of aged male rats
109. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats
110. Breast tumor aromatase: Functional role and transcriptional regulation
111. Examination of POU homeobox gene expression in human breast cancer cells